Repigut 20 and 40 mg Gastric-resistant tablets.
PDF Leaflet Revision Date: 07 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Gastro-Oesophageal Reflux Disease (GORD) and prevention of gastric ulcers.
Dosage (summary)
40 mg once daily for 4 weeks for erosive reflux; 20 mg once daily for maintenance.
Onset of Action / Duration
Onset: 1 hour, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Safety not established during pregnancy and lactation.
Key Drug Interactions
- Clopidogrel
- Warfarin
- Digoxin
- Atazanavir
- Nelfinavir
Contraindications
- Hypersensitivity to esomeprazole
- Concomitant use with atazanavir or nelfinavir
Common side effects
- Headache
- Abdominal pain
- Diarrhoea
- Nausea
Counselling Points
- Take whole with liquid
- Monitor magnesium levels if on long-term therapy
- Avoid alcohol
Serious warnings
- Risk of acute interstitial nephritis
- Severe hypomagnesaemia
- Increased risk of fractures
Important Disclaimer
The Repigut 20 and 40 mg Gastric-resistant tablets. professional information leaflet below is the property of Pharma-Q Holdings and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
